This study compares a targeted radiation treatment (PRRT with 177Lu-Edotreotide) to the best standard care for people with aggressive neuroendocrine tumors of the gut or pancreas. About 259 adults with tumors that have specific markers (SSTR+) will be enrolled. The goal is to see…
Phase: PHASE3 • Sponsor: ITM Solucin GmbH • Aim: Disease control
Last updated May 22, 2026 13:51 UTC